Proactive Investors - Run By Investors For Investors

Alliance Pharma reports strong growth as it launches UK's first prescribed drug for morning sickness

Peter Butterfield, chief executive of Alliance Pharma plc (LON:APH), updates Proactive's Andrew Scott on the group's first half performance.

A strong performance from its portfolio of international brands boosted first-half sales.

Turnover rose by 10% to £54.5m (2017: £49.4m) with scar tissue treatment Kelo-cote seeing sales rise by 77% while eye supplement Macushield was 22% ahead of a year ago.

Since June they've also launched the UK’s only prescription treatment for vomiting and nausea during pregnancy.

Sold under the brand name Xonvea, Diclectin was licensed from Duchesnay of Canada in 2015 and has been prescribed to 33mln women over 40 years.

View full APH profile View Profile

Alliance Pharma PLC Timeline

January 21 2019
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use